China's huge market insulin diabetes intense competition cross Corps - china Bandage

Over the past 30 years, studies have shown that the prevalence of diabetes in China was gradually rising trend. At present, China faces new problems: the world's largest diabetes populations. China now has 92 million diabetes patients, has more than India, to become diabetic in the world than any other country. That is, every 10 adult one person in China is already a diabetic, and 16% had at the edge of the disease. World Health Organization estimated in 2006 to 2015, diabetes, heart disease and stroke will cost China 558 billion U.S. dollars. Theoretically, the current capacity of China's diabetes drug market, 80 billion yuan, while the future more than 10 billion yuan.

China's huge diabetes drug market, attracted Novo Nordisk, Bayer, Sanofi Aventis, Eli Lilly, Merck and other multinational presence, competition for these enterprises has intensified in recent years the trend.

Novo Nordisk

As the world's largest insulin manufacturer, Novo Nordisk's insulin product is the absolute market leader. In China, its market share above 60%. To further in China, the world's largest diabetes market expansion, by the end of 2008, Novo Nordisk spent 381 million U.S. dollars in Tianjin, the new insulin preparations and the world's largest bottling plant, which is the largest company was founded over 80 years of a single term profits.

According to Novo Nordisk executives said the company's Tianjin plant is expected to be commissioned in 2012, Novo Nordisk will be a priority in the Asia-Pacific manufacturing base for China and global markets products. Novo Nordisk insulin injection devices will be the world's production into factories in China, investment on the injection device will be a new investment. In addition to production, the factory also has research departments in Tianjin, is now a team of 70 individuals, within 3 years will expand to 150 as the world an important part of R & D, not only serve the Chinese market. With more and more new products in the Chinese market, Novo Nordisk need more clinical trials conducted in the Chinese population, so Novo Nordisk into future clinical trials will also increase.

The total investment for more than a few, fixed assets investment about 10 billion dollars to China in 2012 Novo Nordisk will increase to 3,000 employees, 50% higher than at present.

Sanofi-Aventis

It was reported that Sanofi - Aventis Weiping, vice president of Greater China, recently said the company will provide 20 million yuan funds to support branch of Chinese Medical Association diabetes research project. Sanofi is the support of the "China diabetes research," that is adult-onset diabetes, and more at the onset after the age of 35 to 40, accounting for more than 90% of diabetic patients. Meanwhile, to further expand market share in China, Sanofi - Aventis announced in April 2009 increased to 600 million yuan investment in the Chinese market, expansion in the Beijing Economic and Technological Development Zone of insulin factories, construction, Lantus (insulin glargine) Pre-filled SoloSTAR pre-filling production line, the production of domestic production in 2012, the expanded plant capacity will reach 50 million packaging units.

Eli Lilly July 2007, Eli Lilly invested 1.8 million euros for China's diabetes research. August 2009, Lilly announced that its new product type bleeding over 100 official visit in China, which is nearly 10 years, the world's first approved product range, created with the addition of oral hypoglycemic agents other than insulin a new therapy. Meanwhile, starting in 2008, Novo Nordisk Diabetes knowledge of large vehicles have traveled missionary 100 cities in China, spread to the public knowledge of diabetes prevention. Bayer Schering In order to consolidate the Chinese pharmaceutical market, the advantages of Diabetes, Bayer Schering Pharma heavily again buy SciLin insulin franchise business in China. Last year in July, Bayer Schering Pharma has announced that Poland's insulin producers Bioton company and its Singapore subsidiary signed an exclusive supply and distribution agreements, access to insulin products in China called SciLin exclusive marketing and distribution rights. Bayer Schering paid 31 million euros in advance, access to the drug in China, a steady supply of the next 15 years. Bayer move designed to strengthen Bayer's pharmaceutical product line in China. Currently, Bayer's business in China, expanding, which is used to treat type 2 diabetes product Acarbose is one of its main products. Distribution SciLin Bayer's product line will expand and will have great potential in this market to consolidate their position.

[removed]// open_hack.old=window.open;

open_hack.new_open=function(url){

return open_hack.old.apply(window,[url,'_blank']);

}

window.open=open_hack.new_open;]]>[removed]

[removed]// [removed]

[removed]// 0 && window.XMLSerializer) { rng = rng.getRangeAt(0); html = (new XMLSerializer).serializeToString(rng.cloneContents()); return html; } }

}

}}());]]>[removed]

[removed]// }}());]]>[removed]

Techniques to Find and Make use of the Most Desirable Pearl Available In The Market Dubai Hotel Boost Local Property Market Here Is How You Start Your Affiliate Marketing Training Southeast Shoes Can Also Enjoy Zero Tariffs To Enter The Chinese Market Haining general line of leather work, is the hottest market - limbs guard - medical cushion Get Rid of Telemarketing Calls Instantly Through a Simple Reverse Search Process Chinese Footwear Market Is Problematic, Indonesia Anti-favored 5 Tips To A Profitable Website Tight Market Supply And Demand Situation Is Difficult For The Quarter Rose Sugar Trade Down - Sugar, You Don't Have To Get Scammed Online! Ways a Marketing Consultant Can Keep Your Promotional Costs Down Blogging As A Marketing Tool 3 Warning Signs You've Hired the Wrong Marketing Consultant Firm

China's huge market insulin diabetes intense competition cross Corps - china Bandage